Guo Yan, Strickland Stephen A, Mohan Sanjay, Li Shaoying, Bosompem Amma, Vickers Kasey C, Zhao Shilin, Sheng Quanhu, Kim Annette S
a Center for Quantitative Sciences , Vanderbilt University , Nashville , TN , USA.
b Department of Medicine, Division of Hematology/Oncology , Vanderbilt University Medical Center , Nashville , TN , USA.
Leuk Lymphoma. 2017 Sep;58(9):1-15. doi: 10.1080/10428194.2016.1272680. Epub 2017 Jan 13.
Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders of the elderly that carry an increased risk of progression to acute myeloid leukemia (AML). Since small non-coding RNAs (sRNAs), including microRNA (miRNAs), act as regulators of cellular differentiation, we hypothesized that changes to sRNAs might be implicated in the progression of MDS to AML. We conducted sRNA sequencing on three sets of patients: Group A (MDS patients who never progressed to AML); Group B (MDS patients who later progressed to an AML); and Group C (AML patients with myelodysplasia-related changes, including patients with a known preceding diagnosis of MDS). We identified five miRNAs that differentiated Groups A and B, independent of bone marrow blast percentage, including three members of the miR-181 family, as well as differential patterns of miRNA isoforms (isomiRs) and tDRs. Thus, we have identified sRNA biomarkers that predict MDS cases that are likely to progress to AML.
骨髓增生异常综合征（MDS）是老年人的克隆性造血疾病，进展为急性髓系白血病（AML）的风险增加。由于包括微小RNA（miRNA）在内的小非编码RNA（sRNA）作为细胞分化的调节因子，我们推测sRNA的变化可能与MDS进展为AML有关。我们对三组患者进行了sRNA测序：A组（从未进展为AML的MDS患者）；B组（后来进展为AML的MDS患者）；C组（有骨髓增生异常相关改变的AML患者，包括先前已知诊断为MDS的患者）。我们鉴定出5种可区分A组和B组的miRNA，与骨髓原始细胞百分比无关，包括miR-181家族的3个成员，以及miRNA异构体（isomiRs）和tDR的差异模式。因此，我们已经鉴定出可预测可能进展为AML的MDS病例的sRNA生物标志物。
